Basic information Safety Supplier Related

1H-Benz[de]isoquinoline-2(3H)-butanamide

Basic information Safety Supplier Related

1H-Benz[de]isoquinoline-2(3H)-butanamide Basic information

Product Name:
1H-Benz[de]isoquinoline-2(3H)-butanamide
Synonyms:
  • 1H-Benz[de]isoquinoline-2(3H)-butanamide, N-hydroxy-1,3-dioxo- (9CI)
  • 1H-Benz[de]isoquinoline-2(3H)-butanamide, N-hydroxy-1,3-dioxo-
  • script
  • Nullscript, Inactive analog of scriptaid
CAS:
300816-11-9
MF:
C16H14N2O4
MW:
298.29
Mol File:
300816-11-9.mol
More
Less

1H-Benz[de]isoquinoline-2(3H)-butanamide Chemical Properties

Melting point:
171-172℃
storage temp. 
−20°C
solubility 
≤2mg/ml in DMSO;2mg/ml in dimethyl formamide
form 
Yellow to off-white solid.
Sensitive 
Light Sensitive
More
Less

Safety Information

Safety Statements 
22-24/25
More
Less

1H-Benz[de]isoquinoline-2(3H)-butanamide Usage And Synthesis

Definition

ChEBI: 4-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxybutanamide is a member of isoquinolines.

Biological Activity

nullscript is an hdac inhibitor.histone deacetylase inhibitors (hdis) have been used in psychiatry and neurology as mood stabilizers and anti-epileptics, such as valproic acid. recently, hdis are being studied as a mitigator or treatment for neurodegenerative diseases. moreover, there has been an effort to develop hdis for cancer therapy.

in vitro

nullscript, a close analog of scriptaid, was found to be inactive in transcriptional facilitation at corresponding concentrations, which confirmed a minimal requirement for the length of the linker chain expected for this class of hdac inhibitors. in addition, nullscript was not able to induce the p6sbe-luc reporter construct, which was identified from the library using chemfinder by its structural similarity to scriptaid [1].

in vivo

a standard in vivo model of cardiac i/rwe was utilized to examine the in vivo consequences of hdac inhibition in the intact heart. results showed that the treatment with scriptaid led to a nearly identical effect when compared to nullscript, with a 46.8% reduction in infarct size. such results strongly suggested that in murine models, hdacis could reverse the induction of ischemia-induced hdac activity and reduced myocardial infarct size by more than 50% [2].

References

[1] g. h. su, t. a. sohn, b. ryu, et al. a novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. cancer research 60, 3137-3142 (2000).
[2] anne granger et al. histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. faseb j. 2008 oct; 22(10): 3549–3560.

1H-Benz[de]isoquinoline-2(3H)-butanamideSupplier

Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
Amadis Chemical Company Limited
Tel
571-89925085
Email
sales@amadischem.com
BOC Sciences
Tel
Email
info@bocsci.com
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
Tel
18818260767
Email
sales@chemegen.com
MedBioPharmaceutical Technology Inc
Tel
021-69568360 18916172912
Email
order@med-bio.cn